Interest in antibody drug conjugates (ADC) is surging with more combined MAb and warhead candidates entering clinical trials than ever before.
The biopharmaceutical industry has had a difficult few years with ADCs.
There have been successes like Besponsa (inotuzumab ozogamicin) – which Pfizer cited as a driver in 2018 – and Roche and Seattle Genetics’ Polivy (polatuzumab vedotin-piiq) which won fast-track approval in the US this year.
Likewise, Kadcyla (trastuzumab emtansine) – also made by Roche – has been cleared for new indications since it was first approved in 2013.
But there have also been ADC failures. Just ask Abbvie.
In 2016, AbbVie spent $5.8bn to acquire Stemcentrx, citing its candidate lung cancer ADC Rova-T as a major driver. However, in August Abbvie halted development after the drug demonstrated no survival benefit.
Then there is Pfizer’s Mylotarg (gemtuzumab ozogamicin), which is perhaps the best example of the ebb and flow seen in the ADC sector.
Wyeth and partner Celltech first won approval for Mylotarg in 2000 when the US Food and Drug Administration (FDA) cleared it for acute myeloid leukemia (AML).
However, in 2017 Pfizer successfully sought re-approval for Mylotarg at a lower recommended dose, different schedule and in a new patient population.
ADCs in trials
Clearly developing ADCs is not straightforward.
However, industry has far from given up on such products says Jia He, senior analyst at consulting firm Beacon Targeted Therapies.
“ADCs are experiencing a resurgence of renewed faith in the therapy. We’ve seen more trials initiated and ADCs enter the clinic this year than in previous years,” He said, explaining that 45 started clinical trials in in 2017 and 73 in 2018.
She added that, “The ADC market as of October 2019 stands at 226 assets in development, 88 in the clinic and 178 at the preclinical stage with 75 trials being conducted currently year to date.”
Whether many, or any, of these candidates wins approval remains to be seen.
Some developers have already had second thoughts He says.
“With growth comes challenges, and so far there have been four ADCs that have been discontinued with an official announcement and 10 that have been removed from pipeline without further announcement. Thirteen trials that have been terminated, suspended or withdrawn this year.”
But there is also reason for optimism He says, highlighting Daiichi-Sankyo and AstraZeneca’s DS-8201, Seattle Genetics and Astellas’ enfortumab vedotin and ImmunoGen’s mirvetuximab soravtansine as drugs to watch.
Resurgent interest in ADCs is having a wider impact according to He, who cites Roche’s successful expansion of Kadcyla’s indication as a driver of technology development.
“After the clinical success of Kadcyla, it was clear that HER2 targeting MAbs would become a popular antibody choice for ADC developers. It’s triggered development into novel linkers and payloads with varying mechanisms of actions.”
As yet few second generation candidates have entered trials according to He, who told us “the clinic is still dominated by first generation techniques that deploy stochastic conjugation to multiple natural lysines or cysteines on mAbs.
“We are starting to see novel technologies such as site specific conjugation, natural and non-natural amino acid conjugation are starting to be tested in the clinic,” she said.